Decibel Therapeutics to Present at Upcoming Investor Conferences
02. September 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
18. August 2021 07:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
10. August 2021 07:30 ET
|
Decibel Therapeutics, Inc.
- Bolstered Board of Directors and Scientific Advisory Board with key appointments - - On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim...
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
02. Juni 2021 08:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Expands World-Class Scientific Advisory Board
24. Mai 2021 16:15 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
19. Mai 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update
13. Mai 2021 17:05 ET
|
Decibel Therapeutics, Inc.
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
28. April 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08. April 2021 08:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
29. März 2021 16:05 ET
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...